Farabi Pharmaceutical (XTEH:DFRB1) Notes Receivable: IRR0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Farabi Pharmaceutical Notes Receivable?

Farabi Pharmaceutical XTEH:DFRB1 Notes Receivable is IRR0.00 Mil as of . 20.

Farabi Pharmaceutical's Notes Receivable for the quarter that ended in . 20 was IRR0.00 Mil.

Farabi Pharmaceutical Notes Receivable Related Terms

Farabi Pharmaceutical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical Notes Receivable Chart

Farabi Pharmaceutical Annual Data
Trend
Notes Receivable

Farabi Pharmaceutical Quarterly Data
Notes Receivable

Farabi Pharmaceutical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of IRR0.00 Mil mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Notes Receivable of IRR0.00 Mil as of . 20. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Notes Receivable too high?
Farabi Pharmaceutical's current Notes Receivable is IRR0.00 Mil.
How does Farabi Pharmaceutical's Notes Receivable compare to IMNPQ and INNV?
Farabi Pharmaceutical's Notes Receivable of IRR0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current Notes Receivable is IRR0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Notes Receivable of IRR0.00 Mil. The current Notes Receivable is IRR0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Notes Receivable is IRR0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.